Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2CNS 2Lymphoid 1

Conditions

Lung Neoplasms 2Respiratory Aspiration 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 1145Cisplatin 874Pemetrexed 832pembrolizumab 604Paclitaxel 597Docetaxel 535Gemcitabine 424Radiotherapy 374Erlotinib Hydrochloride 367Nivolumab 322Bevacizumab 322Etoposide 294durvalumab 254Drug Therapy 233osimertinib 217atezolizumab 207Radiosurgery 188Gefitinib 177Vinorelbine 145130-nm albumin-bound paclitaxel 123Magnetic Resonance Spectroscopy 120Ipilimumab 118Cetuximab 113anlotinib 104tislelizumab 103Topotecan 101Cyclophosphamide 101Taxes 99Irinotecan 95Albumin-Bound Paclitaxel 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Inhalation × Thoracic × Clear all
NCT06896890 2025-03-26

Cisplatin (CIS) Administered As Dry Powder for Inhalation (DPI) in Patients with Stage IV Non-Small Cell Lung Cancer

Inhatarget Therapeutics

Phase 1/2 Recruiting
32 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Respiratory Aspiration

NCT00210080 2015-09-04

A Study to Diagnose Lung Cancer by Sputum Cytology (01-312)

Merck Sharp & Dohme LLC

Phase 3 Completed
700 enrolled
Thoracic

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡